Trial of Vitamin D Fortified Milk
A Randomized Trial of Milk Fortified With Vitamin D in Colombia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bogota, Colombia
- FINUSAD - Foundation for Research in Nutrition and Health
-
Chia, Colombia
- University of La Sabana
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 144 and 174 completed months by the time of enrollment.
- Intention to stay in the city for the next six weeks.
- Children living with their biological mothers.
- Families own a refrigerator.
Exclusion Criteria:
- History of illness involving calcium or bone metabolism, including stones of the urinary tract.
- Currently taking vitamin D supplements as treatment of any disease.
- Receiving immunosuppressive therapy (oral corticosteroids, chemotherapy) during the previous year.
- Known history of lactose intolerance or other contra-indications or aversion to milk intake.
- Known hypercalcemia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Vitamin D-fortified milk
Skim milk fortified with 600 IU vitamin D3 / 250 mL
|
|
|
Active Comparator: Vitamin D-unfortified milk
Unfortified skim milk
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Serum concentrations of 25-OH vitamin D
Time Frame: up to 6 weeks
|
up to 6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Mercedes Mora, MSc, RD, FINUSAD - Foundation for Research in Nutrition and Health
- Study Director: Henry Oliveros, MD, MSc, University of La Sabana
- Principal Investigator: Eduardo Villamor, MD, DrPH, University of Michigan
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- VDFORT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on 25-hydroxyvitamin D Serum Concentrations
-
NCT02150122CompletedSerum 25-hydroxyvitamin D Concentrations (25OHD)
-
NCT02212223CompletedSerum 25-hydroxyvitamin D Concentrations (25OHD)
-
NCT02525003CompletedSerum 25-hydroxyvitamin D Concentrations (25OHD)
-
NCT02445066CompletedLow 25-hydroxyvitamin D Concentrations
-
NCT01398202CompletedVitamin D Status as Reflected by Serum 25-hydroxyvitamin D
-
NCT01919905CompletedChange in Serum 25 Hydroxyvitamin D Levels
-
NCT04174625Completed25-hydroxyvitamin D Levels
-
NCT02495584Completed25-hydroxyvitamin D Concentration (Vitamin D Status)
-
NCT01555424UnknownThe Focus is to Assess 25-hydroxyvitamin D Levels and Well-being
-
NCT03537027CompletedVitamin D Receptor Target Gene Expression | Serum 25(OH)D Concentration
Clinical Trials on Vitamin D
-
NCT07598032Not yet recruitingProstate Cancer (Adenocarcinoma) | Vitamin D on Tumor Response and Inflammatory Markers
-
NCT00249704Terminated
-
NCT07310329CompletedAthletes | Football Players | Exercise Physiology | Vitamin D Deficiency (10 ng/mL to 30 ng/mL)
-
NCT07275177CompletedObesity | Muscle Weakness | Vitamin D Deficiency | Sarcopenia | Aging | Sarcopenic Obesity | Obesity (Disorder) | Sarcopenia in Elderly | Muscle Mass | Functional Decline
-
NCT01741324Completed
-
NCT07579078Enrolling by invitationHypovitaminosis D | Major Depressive Disorder (MDD)
-
NCT07535671Active, not recruitingThose Who Provided Written Informed Consent | Female Gender | Aged 18 Years and Older | Hypothyroidism Disease | Serum Vitamin d < 30 ng/dl
-
NCT06289257CompletedEndometriosis | Vitamin D Status | Vitamin D Deficiency/Insufficiency
-
NCT07641075RecruitingVitamin D Deficiency/Insufficiency | Vitamin D 25-Hydroxylase Deficiency
-
NCT04394390Completed